SEC Tracker
Get the app

MaxCyte MXCT

MaxCyte FY 2021: revenue $33.9M; diluted EPS −$0.21

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers MaxCyte reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$33.9MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Net income−$19.1MNo year-earlier figure tagged10-K income statement, on EDGAR
  3. Diluted EPS−$0.21No year-earlier figure tagged10-K income statement, on EDGAR
  4. Cash and cash equivalents$47.8MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  5. Cash from operations−$10.7MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when MaxCyte files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8731 and related industry codes: the same peer list as the financial tables.

  1. NRC Health NRC public float $195M, Jun 30, 2025
  2. Absci ABSI public float $304M, Jun 30, 2025
  3. OmniAb OABI public float $145M, Jun 30, 2025
  4. Neogenomics NEO public float $680M, Jun 30, 2025
  5. Inotiv NOTV public float $71M, Mar 31, 2025, over 18 months old